These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 38339026)

  • 21. Familial clustering of primary lateral sclerosis and amyotrophic lateral sclerosis: Supplementary evidence for a continuum.
    Corcia P; Lunetta C; Couratier P; Vourc'h P; Gromicho M; Desnuelle C; Soriani MH; Pinto S; de Carvalho M
    Eur J Neurol; 2021 Aug; 28(8):2780-2783. PubMed ID: 34110677
    [TBL] [Abstract][Full Text] [Related]  

  • 22. "Switchboard" malfunction in motor neuron diseases: Selective pathology of thalamic nuclei in amyotrophic lateral sclerosis and primary lateral sclerosis.
    Chipika RH; Finegan E; Li Hi Shing S; McKenna MC; Christidi F; Chang KM; Doherty MA; Hengeveld JC; Vajda A; Pender N; Hutchinson S; Donaghy C; McLaughlin RL; Hardiman O; Bede P
    Neuroimage Clin; 2020; 27():102300. PubMed ID: 32554322
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Update on the pathological roles of prostaglandin E
    Nango H; Tsuruta K; Miyagishi H; Aono Y; Saigusa T; Kosuge Y
    Transl Neurodegener; 2023 Jun; 12(1):32. PubMed ID: 37337289
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuroprotective effects of the Sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation.
    Peviani M; Salvaneschi E; Bontempi L; Petese A; Manzo A; Rossi D; Salmona M; Collina S; Bigini P; Curti D
    Neurobiol Dis; 2014 Feb; 62():218-32. PubMed ID: 24141020
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Motor neuron dysfunction in a mouse model of ALS: gender-dependent effect of P2X7 antagonism.
    Cervetto C; Frattaroli D; Maura G; Marcoli M
    Toxicology; 2013 Sep; 311(1-2):69-77. PubMed ID: 23583883
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Amyotrophic Lateral Sclerosis (ALS) and Related Motor Neuron Diseases: An Overview.
    Morris J
    Neurodiagn J; 2015 Sep; 55(3):180-94. PubMed ID: 26630810
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Small molecules targeting different cellular pathologies for the treatment of amyotrophic lateral sclerosis.
    Elmansy MF; Reidl CT; Rahaman M; Özdinler PH; Silverman RB
    Med Res Rev; 2023 Nov; 43(6):2260-2302. PubMed ID: 37243319
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amyotrophic Lateral Sclerosis: Autoimmune Pathogenic Mechanisms, Clinical Features, and Therapeutic Perspectives.
    Ralli M; Lambiase A; Artico M; de Vincentiis M; Greco A
    Isr Med Assoc J; 2019 Jul; 21(7):438-443. PubMed ID: 31507117
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Molecular Link Between TDP-43, Endogenous Retroviruses and Inflammatory Neurodegeneration in Amyotrophic Lateral Sclerosis: a Potential Target for Triumeq, an Antiretroviral Therapy.
    Dubowsky M; Theunissen F; Carr JM; Rogers ML
    Mol Neurobiol; 2023 Nov; 60(11):6330-6345. PubMed ID: 37450244
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biological aspects of nitrogen heterocycles for amyotrophic lateral sclerosis.
    Manjupriya R; Pouthika K; Madhumitha G; Roopan SM
    Appl Microbiol Biotechnol; 2023 Jan; 107(1):43-56. PubMed ID: 36480040
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Time for optimism in amyotrophic lateral sclerosis.
    Corcia P; Lunetta C; Vourc'h P; Pradat PF; Blasco H
    Eur J Neurol; 2023 May; 30(5):1459-1464. PubMed ID: 36773012
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Infectious agents and amyotrophic lateral sclerosis: another piece of the puzzle of motor neuron degeneration.
    Castanedo-Vazquez D; Bosque-Varela P; Sainz-Pelayo A; Riancho J
    J Neurol; 2019 Jan; 266(1):27-36. PubMed ID: 29845377
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Implications of white matter damage in amyotrophic lateral sclerosis (Review).
    Zhou T; Ahmad TK; Gozda K; Truong J; Kong J; Namaka M
    Mol Med Rep; 2017 Oct; 16(4):4379-4392. PubMed ID: 28791401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In a search for efficient treatment for amyotrophic lateral sclerosis: Old drugs for new approaches.
    Kukharsky MS; Skvortsova VI; Bachurin SO; Buchman VL
    Med Res Rev; 2021 Sep; 41(5):2804-2822. PubMed ID: 32815157
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The role of lipids in the pathogenesis of lateral amyotrophic sclerosis].
    Alessenko AV; Gutner UA; Nebogatikov VO; Shupik MA; Ustyugov AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(10):108-117. PubMed ID: 33244966
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Riluzole for the treatment of amyotrophic lateral sclerosis.
    Saitoh Y; Takahashi Y
    Neurodegener Dis Manag; 2020 Dec; 10(6):343-355. PubMed ID: 32847483
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patients with amyotrophic lateral sclerosis and cancer do not differ clinically from patients with sporadic amyotrophic lateral sclerosis.
    Vigliani MC; Polo P; Chiò A; Giometto B; Mazzini L; Schiffer D
    J Neurol; 2000 Oct; 247(10):778-82. PubMed ID: 11127533
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amyotrophic lateral sclerosis.
    Valko K; Ciesla L
    Prog Med Chem; 2019; 58():63-117. PubMed ID: 30879475
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A patient-supported strategy for therapy development in amyotrophic lateral sclerosis (ALS).
    Klausmeier WH
    Am J Ther; 2001; 8(5):329-32. PubMed ID: 11550074
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel Selenium-based compounds with therapeutic potential for SOD1-linked amyotrophic lateral sclerosis.
    Amporndanai K; Rogers M; Watanabe S; Yamanaka K; O'Neill PM; Hasnain SS
    EBioMedicine; 2020 Sep; 59():102980. PubMed ID: 32862101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.